Cargando…

Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy

Epithelial ovarian carcinoma (EOC) is highly fatal because of the risk of resistance to therapy and recurrence. We performed whole-exome sequencing of blood and tumor tissue pairs of 50 patients with surgically resected EOC. Compared with sensitive patients, platinum-resistant patients had a signifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hlaváč, Viktor, Holý, Petr, Václavíková, Radka, Rob, Lukáš, Hruda, Martin, Mrhalová, Marcela, Černaj, Petr, Bouda, Jiří, Souček, Pavel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Life Science Alliance LLC 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574568/
https://www.ncbi.nlm.nih.gov/pubmed/36229065
http://dx.doi.org/10.26508/lsa.202201551
_version_ 1784811130765443072
author Hlaváč, Viktor
Holý, Petr
Václavíková, Radka
Rob, Lukáš
Hruda, Martin
Mrhalová, Marcela
Černaj, Petr
Bouda, Jiří
Souček, Pavel
author_facet Hlaváč, Viktor
Holý, Petr
Václavíková, Radka
Rob, Lukáš
Hruda, Martin
Mrhalová, Marcela
Černaj, Petr
Bouda, Jiří
Souček, Pavel
author_sort Hlaváč, Viktor
collection PubMed
description Epithelial ovarian carcinoma (EOC) is highly fatal because of the risk of resistance to therapy and recurrence. We performed whole-exome sequencing of blood and tumor tissue pairs of 50 patients with surgically resected EOC. Compared with sensitive patients, platinum-resistant patients had a significantly higher somatic mutational rate in TP53 and lower in several genes from the Hippo pathway. We confirmed the pivotal role of somatic mutations in homologous recombination repair genes in platinum sensitivity and favorable prognosis of EOC patients. Implementing the germline homologous recombination repair profile significantly improved the prediction. In addition, distinct mutational signatures, for example, SBS6, and overall mutational load, somatic mutations in PABPC1, PABPC3, and TFAM co-segregated with the resistance status, high-grade serous carcinoma subtype, or overall survival of patients. We generated germline and somatic genetic landscapes of prognostically different subgroups of EOC patients for further follow-up studies focused on utilizing the observed associations in precision oncology.
format Online
Article
Text
id pubmed-9574568
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Life Science Alliance LLC
record_format MEDLINE/PubMed
spelling pubmed-95745682022-10-17 Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy Hlaváč, Viktor Holý, Petr Václavíková, Radka Rob, Lukáš Hruda, Martin Mrhalová, Marcela Černaj, Petr Bouda, Jiří Souček, Pavel Life Sci Alliance Research Articles Epithelial ovarian carcinoma (EOC) is highly fatal because of the risk of resistance to therapy and recurrence. We performed whole-exome sequencing of blood and tumor tissue pairs of 50 patients with surgically resected EOC. Compared with sensitive patients, platinum-resistant patients had a significantly higher somatic mutational rate in TP53 and lower in several genes from the Hippo pathway. We confirmed the pivotal role of somatic mutations in homologous recombination repair genes in platinum sensitivity and favorable prognosis of EOC patients. Implementing the germline homologous recombination repair profile significantly improved the prediction. In addition, distinct mutational signatures, for example, SBS6, and overall mutational load, somatic mutations in PABPC1, PABPC3, and TFAM co-segregated with the resistance status, high-grade serous carcinoma subtype, or overall survival of patients. We generated germline and somatic genetic landscapes of prognostically different subgroups of EOC patients for further follow-up studies focused on utilizing the observed associations in precision oncology. Life Science Alliance LLC 2022-10-13 /pmc/articles/PMC9574568/ /pubmed/36229065 http://dx.doi.org/10.26508/lsa.202201551 Text en © 2022 Hlaváč et al. https://creativecommons.org/licenses/by/4.0/This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Articles
Hlaváč, Viktor
Holý, Petr
Václavíková, Radka
Rob, Lukáš
Hruda, Martin
Mrhalová, Marcela
Černaj, Petr
Bouda, Jiří
Souček, Pavel
Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy
title Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy
title_full Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy
title_fullStr Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy
title_full_unstemmed Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy
title_short Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy
title_sort whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574568/
https://www.ncbi.nlm.nih.gov/pubmed/36229065
http://dx.doi.org/10.26508/lsa.202201551
work_keys_str_mv AT hlavacviktor wholeexomesequencingofepithelialovariancarcinomasdifferinginresistancetoplatinumtherapy
AT holypetr wholeexomesequencingofepithelialovariancarcinomasdifferinginresistancetoplatinumtherapy
AT vaclavikovaradka wholeexomesequencingofepithelialovariancarcinomasdifferinginresistancetoplatinumtherapy
AT roblukas wholeexomesequencingofepithelialovariancarcinomasdifferinginresistancetoplatinumtherapy
AT hrudamartin wholeexomesequencingofepithelialovariancarcinomasdifferinginresistancetoplatinumtherapy
AT mrhalovamarcela wholeexomesequencingofepithelialovariancarcinomasdifferinginresistancetoplatinumtherapy
AT cernajpetr wholeexomesequencingofepithelialovariancarcinomasdifferinginresistancetoplatinumtherapy
AT boudajiri wholeexomesequencingofepithelialovariancarcinomasdifferinginresistancetoplatinumtherapy
AT soucekpavel wholeexomesequencingofepithelialovariancarcinomasdifferinginresistancetoplatinumtherapy